Policy

In an era that FDA Commissioner Marty Makary, MD, MPH, calls an "epidemic of distrust" toward health institutions, previously contained disease rates are rapidly rising, and vaccination rates are proceeding in the opposite direction.

The executive order signed on May 12 has some differences from a previous executive order originally signed by the Trump administration in 2020.

A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often represent a significant cost burden for Medicare Part D beneficiaries and which were selected for 2026 drug price negotiation under the Inflation Reduction Act.

The new executive order contains multiple provisions if pharmaceutical companies do not offer "most-favored nation" pricing on medication.

Employers explore innovative strategies at the Greater Philadelphia Business Coalition on Health (GPBCH) Annual Conference, focusing on GLP-1 policies to enhance health care quality and manage costs effectively.

Robert F. Kennedy Jr’s congressional hearing featured numerous statements from the secretary of HHS, including denouncing claims of cutting down the HHS and the National Institutes of Health.

Investing in patient navigation and clinician incentives ensures colorectal cancer screening completion, improves early detection, reduces disparities, achieves cost savings, and advances population health for all stakeholders.

The Trump administration has decided to further debate the federal rule passed during the Biden administration that guaranteed insurance coverage for treatment of mental illness and substance abuse.

Proposed Medicaid cuts in the Republican budget proposal hold significant implications for health care access and coverage.

New studies reveal unmet health care needs and racial disparities, while experts share insight on addressing food insecurity and the shifting health policy landscape.

The move would align prescription costs in the US with the costs of other countries, according to the administration.

Antoine Keller, MD, argued the value of grounding health care policy in equity as clinicians prepare for a changing health care landscape in the coming years.

The Trump administration's termination of 694 NIH grants totaled $1.81 billion by April 2025, generating significant uncertainty and concern regarding the future of US health research, especially for minority populations.

The Ensuring Community Access to Pharmacist Services (ECAPS) Act of 2025 (H.R. 3164) aims to ensure vital pharmacy services and access to care for underserved communities.

The National Comprehensive Cancer Network (NCCN) policy summit highlighted the need for improved communication between oncology and primary care to enhance cancer survivor outcomes and care transitions.

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised concerns over regulatory scrutiny as the biotech market dropped.

Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.

The goal of the proposed bill is to “make prescriptions affordable again” in the US.

Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new administration to how artificial intelligence (AI) is reshaping the patience experience.

The 2025 Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for enhancing community cancer care.

To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The May issue features a conversation with John Michael O’Brien, PharmD, MPH, a member of AJMC’s editorial board and the president and CEO of the National Pharmaceutical Council. This interview has been lightly edited for clarity.

An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.

Mingyang Song, MBBS, ScD, expands upon the link between ultraprocessed foods and cancer risks, emphasizing the need for better dietary choices and further research.

Improving relationships between pharmaceutical makers, health systems, patients, and insurers can help to lower the price of health care for patients, according to John Michael O'Brien, PharmD, MPH.

Kimlin Tam Ashing, PhD, explores how strengthening community engagement can enhance cancer research and inform more effective policy development.